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cord blood). Results: 13 patients have been enrolled: LCH (3), HLH
(2), Wiscott-Aldrich (1), mannosidosis (2), Krabbe’s (1), sickle cell (1),
thalassemia (2), and Kostmann’s (1). Median age  2.2 yearrs (0.4–
9.1). Stem cell sources were: MSD (3), unrelated UCB (3–5/6 HLA
matched, 1–6/6 HLA matched), 6/6 unrelated marrow (5), 6/6 unre-
lated PBSC (1). Thymoglobulin®toxicities were: (1) seizure course
completed and (1) grade IV hypotension (course aborted after two
doses). No other non-hematologic grades 3–4 toxicities were ob-
served. All patients achieved 	90% stable donor chimerism with no
primary or secondary graft failure. Median ANC recovery  15 days
(11–35). Three patients died of infections before day 100. One pateint
developed acute GVHD (grade 2 skin only) and limited chronic
GVHD (the patient with aborted Thymoglobulin® course). Ten
(77%) survived with median follow-up of 410 days (90–1030). Con-
clusions: This preparative regimen is very well tolerated with to date
no graft failure and stable donor chimerism even with cord blood.
Thymoglobulin®appears to provide good in vitro T-cell depletion
with minimal GVHD. Additional patients need to be enrolled to
verify these results.
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COMBINED HOME ENZYME REPLACEMENT THERAPY AND UNRELATED
CORD BLOOD TRANSPLANT FOR HURLER’S SYNDROME (MPSI)
Khimji, I.1, Lepage, C.1, Zalesky, L.2, Jimenez, P.2, Barbouth, D.3,
Elsas, L.3, Delgado, I.3, Briery, B.3, Gordon, P.3, Kleiner, G.I.3 1.
Jackson Memorial Hospital, Miami, FL; 2. Accredo Therapeutics, Fort
Lauderdale, FL; 3. University of Miami School of Medicine, Miami, FL.
Hurler’s syndrome is caused by mutations in the 
iduronidase
gene and results in progressive deterioration of the central nervous
system. Allogeneic bone marrow transplantation before the age of
2 years halts disease progression and prolongs life. Enzyme re-
placement therapy (ERT) reduces lysosomal storage of mucopo-
lysaccharides in the liver and ameliorates extracranial manifesta-
tions of disease. In most instances, ERT occurs in a day hospital
setting. Since enzyme replacement therapy can mitigate airway and
pulmonary manifestation of MPS I, we hypothesized that ERT in
the peri-transplant period (pre-HSCT and immediately post-
HSCT) would decrease transplant related complications. We per-
formed combined ERT and HSCT in a 12 month old boy with
MPSI. The patient received his ﬁrst dose of Aldurazyme at 5
months of age, shortly after MPSI diagnosis. He had received 16
infusions prior to referral to our center. Throughout his pre-
transplant workup, the patient received ERT at the local Trans-
plant House by a visiting nurse. There were no infusion related
toxicities. The patient received a 5/6 unrelated cord blood unit and
engrafted on day12. Hyperacute GVHD was treated successfully
with high dose methylprednisolone pulse. Following engraftment,
the child received 8 additional doses of Aldurazyme. One year
following transplant, he continues to have normal urine GAGs,
normal enzyme level, and continues to have developmental im-
provements. We conclude that in this case of combined outpatient
ERT infusion with HSCT, pre- and post-transplant ERT does not
interfere with engraftment or developmental improvements.
371
BONE MARROW TRANSPLANTATION IN A CHILD WITH TYPE C OF
NIEMANN-PICK DISEASE (SECOND CASE IN THE WORLD)
Iravani, M.1, Nedaeifard, L.1, Alimoghaddam, K.1, Mousavi, A.1,
Karimi, M.1, Ghavamzadeh, A.1 1Hematology-Oncology and BMT
Research Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Niemann-Pick Disease Type C (NPC) is a lysosomal storage
disease caused by an error in cellular trafﬁcking of exogenous
cholesterol resulting in accumulation of unesteriﬁed cholesterol.
Hematopoietic stem cell transplantation for Niemann-Pick disease
is considered experimental, investigational, and unproven. We
report a 4-years 7 and months old girl with Niemann-Pick type C
disease who received an allogeneic BMT. Her disease presented
with prolonged neonatal icter, hepatosplenomegaly, failure to
thrive, and progressive neurodevelopmental delay from 2 years
ago. Bone marrow biopsy revealed abundant lipid-ﬁlled foamy
macrophages. Her serum sphingomyelinase assey was normal. She
received hematopoietic stem cells from a healthy HLA-identical
female sibling, 19 year old, donor. She had neutrophil recovery
(WBC0.5 109/L) at day 17 and platelet recovery (platelet	 20
109/L) at day 33 after transplantation. She had grade 1 skin
GVHD. She had no serious infection or complication and was
discharged after 38 days. Full engraftment was evidenced by re-
gression of the hepatosplenomegaly, markedly reduced foamy mac-
rophage inﬁltration in bone marrow, and STR-PCR of 90% (Short
Tandem Repeat-polymerase chain reaction) at day 30. She has not
had any serious problems except blood transfusion twice because of
anemia, since transplantation 3 months ago. Her donor has shown
symptoms of Multiple Sclerosis disease two months after trans-
plantation. Follow-up will show the long term effect of BMT on
her disease and neurocognitive development.
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CHEDIAK-HIGASHI SYNDROME: COMPLETE ENGRAFTMENT AFTER
DOCUMENTED CHIMERISM
Ikeda, A.K.1, Roberts, R.L.1, Campbell, K.J.1, Cheng, J.C.1,
Moore, T.B.1 1Mattel Children’s Hospital at UCLA, Los Angeles, CA.
We describe a 7 year old male with a history of Chediak-Higashi
syndrome who received a matched unrelated cord stem cell trans-
plantation in the accelerated phase and achieved complete donor
engraftment after initial partial chimerism. Chediak-Higashi syn-
drome is a rare autosomal disease characterized by partial oculo-
cutaneous albinism, recurrent bacterial infections, mild bleeding
diatheses, and both central and peripheral neuropathies. In late
childhood, these patients develop an accelerated phase character-
ized by pancytopenia, hepatosplenomegaly, and lymphocytic inﬁl-
trates. Death associated with the accelerated phase is secondary to
infection and hemorrhage. The diagnosis of Chediak-Higashi syn-
drome is made by microscopic visualization of the giant cytoplas-
mic granules in leukocytes or abnormal giant melanosomes in hair
shafts. Curative treatment entails bone marrow transplantation.
Hematopoietic chimeras have been documented with clinical im-
provement, particularly being free of the accelerated phase. Our
patient demonstrated chimerism at 30 days post-transplantation.
The DNA ﬁngerprinting analysis at this time showed 30% donor
and 70% recipient cells in the marrow. The neutrophils on the
peripheral blood smear, which contained large purplish inclusion
bodies, were far fewer than the number of normal neutrophils. At
day 77, the peripheral smear showed normal neutrophils and no
granulated leukocytes. Repeat bone marrow biopsy at 84 days
post-transplant showed complete engraftment; 90% donor mar-
row. Although hematopoietic chimerism may result in signiﬁcant
clinical improvement of patients with Chediak-Higashi, there may
be further self-selection for normal marrow cells over abnormal
cells even after the initial engraftment of bone marrow transplan-
tation.
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UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANTATION IN
TWO CHILDREN WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA
WITH RADIO-ULNAR SYNOSTOSIS
Staba, S.L.1, Sola, M.C.1, William, S.B.1 1University of Florida,
Gainesville, FL.
Congenital amegakaryocytic thrombocytopenia (CAMT) with
proximal radio-ulnar synostosis is a rare autosomal dominant dis-
order of thrombopoiesis and forearm abnormality. Four children
have previously been described in the literature, some with an
identiﬁed mutation of the HoxA11 gene. The fathers of the pre-
viously reported children had skeletal abnormalities, however nor-
mal platelet counts. We describe 2 children from the same family
who had radio-ulnar synostosis and CAMT and subsequently un-
derwent unrelated donor umbilical cord blood transplant (UCBT).
The mother has radio-ulnar synostosis without any hematologic
ﬁndings. Both children lack HOXA11 mutations and demonstrated
proximal radio-ulnar sysnostosis. The ﬁrst child had thrombocy-
topenia at birth, with a bone marrow initially showing normal
cellularity with signiﬁcantly decreased megakaryocytes. She pro-
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gressed to severe marrow hypoplasia prior to undergoing a 4/6
HLA matched UCBT at 7 months of age. She was platelet and
packed red blood cell dependent as well as neutropenic. Prior to
cord blood transplant she had a number of bacterial infections, and
ultimately died on day 18 of overwhelming sepsis with Entero-
coccus gallinarum and extensive clotting of her descending aorta,
kidneys and pulmonary vasculature. The second child also showed
signs of throbocytopenia immediately after birth, and received
platelet transfusions prior to transplant. She had multiple infec-
tions with bacterial organisms. Her bone marrow showed minimal
megakaryocytes with initially normal cellularity, however prior to
UCBT her marrow cellularity started to decrease. Due to her
sisters disease progression, she underwent a 6/6 HLA matched
UCBT at 4 months of age. She engrafted on day 16. She had
complications including and early Candidal bacteremia, a seizure
and renal toxicity. She completely recovered and is currently more
than one year post transplant, well engrafted with full donor
chimerism and no evidence of GVHD. Following engraftment she
has not had further infections and appears to be developmentally
normal. Our two patients represent a variant of CAMT with
radio-ulnar synostosis lacking the HOXA11 mutation. We specu-
late they may have had an immune deﬁciency as evidenced by their
extensive infection history, which resolved after transplant in the
surviving child. Unrelated donor cord blood transplant appears to
be a curative option for these children, and proceeding to trans-
plant earlier may improve outcome.
SOLID TUMORS
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS
GERM CELL TUMORS: LONG TERM FOLLOW-UP OF A MULTI-CENTER
EXPERIENCE
Doocey, R.1, Seftel, M.2, Barnett, M.1, Bredeson, C.2, Forrest, D.1,
Hogge, D.1, Lavoie, J.1, Nantel, S.1, Nevill, T.1, Shepherd, J.1,
Sutherland, H.1, Toze, C.1, Smith, C.1, Song, K.1 1. Division of
Hematology, Leukemia/Bone Marrow Transplant Program of British
Columbia, The Vancouver Hospital and Health Science Centre, Vancou-
ver, BC, Canada; 2. Manitoba Blood and Marrow Transplant Program
and CancerCare Manitoba, Winnipeg, MB, Canada.
High dose chemotherapy followed by autologous stem cell rescue
(autoSCT) has been used to provide long term disease control for
patients with poor prognosis germ cell tumors (GCT). Seventy-
one adult males from the Leukemia/BMT program of British
Columbia (n  54) and the Manitoba Blood and Marrow trans-
plant program (n  17) underwent autoSCT for GCT between
03/86 and 02/04. Median age at autoSCT was 31 years (range
16–58). Histological subtype included non-seminoma (n 67) and
pure seminoma (n  4). Fourteen patients presented with primary
extragonadal GCT involving mediastinum (n  11), retroperito-
neum (n  1), and central nervous system (n  2). Nine patients
proceeded straight to autoSCT after a suboptimal PR to induction
chemotherapy. The remaining 62 patients achieved acceptable
responses to initial therapy only to have clear evidence of relapsed
disease either by radiological or tumor marker progression. Dis-
ease status at the time of autoSCT was ﬁrst partial remission (n 
15), recurrent chemosensitive disease (n 51), recurrent chemore-
sistant disease (n  4), and recurrent untested disease (n  1). At
the time of autoSCT, tumor makers were normal in 44 patients
and elevated in 27 patients. High dose chemotherapy for patients
with nonseminomatous histology was etoposide 3.0 g/m2, carbo-
platin 0.8–1.2 g/m2, and ifosfamide 6.0 g/m2 or cyclophosphamide
7.2 g/m2. The 4 patients with pure seminoma received cyclophos-
phamide 7.2 g/m2 and carboplatin 1.5 g/m2. Stem cell source was
BM (n  38), PB (n  31), or both (n  2). At a median follow-up
of 7 years (range 1–18), 29 patients are alive and in remission.
Thirty-one patients have relapsed post autoSCT. The 5 year EFS
and OS for the entire 71 patients is 43% (95% CI 31-54%) and
44% (95% CI 32–55%), respectively. Extragonadal presentation
was associated with a signiﬁcantly reduced 5 year EFS (14% vs
50% P  .001) and OS (14% vs 51% P  .007). A completely
normal tumor marker remission at the time of autoSCT was
associated with a signiﬁcantly higher 5 year EFS (63% vs 14% P 
.001) and OS (63% vs 17% P  .001). The TRM at 5 years was
13% (95% CI 6%–22%). Four patients developed secondary ma-
lignancies post autoSCT. This retrospective review of a large
number of patients with extended follow up demonstrates auto-
SCT to be an effective treatment for patients with relapsed GCT
who can achieve tumor marker negativity. Extragondal presenta-
tions and failure to achieve a tumor marker negative remission
pre-autoSCT are associated with extremely poor outcomes.
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NON-VIRAL TRANSFECTION OF IMMATURE DENDRITIC CELLS WITH
GD2 mRNA ELICITS AN ALLOGENEIC IMMUNE RESPONSE
Stephan, B.1, Horvat-Switzer, R.1, Kletzel, M.1,2 1. Children’s Memo-
rial Research Center, Chicago, IL; 2. Northwestern University, Chicago,
IL.
Vaccination with tumor antigen-loaded Dendritic cells (DC) has
been shown to induce a CD4 T helper cell (Th1) response. The
purpose of this study is to develop a non-viral method of
transfecting DC with mRNA encoding for GD2 and measure
the difference between autologous and allogeneic Th1 response.
Immature DC were generated from CD14 cells from human
peripheral blood in RPMI media containing 10% fetal bovine
serum, 1X pen-strep, granulocyte-macrophage stimulating fac-
tor (GM-CSF), and Interlukin-4 (IL-4). Immature DC were
characterized by ﬂow cytometry and were negative for CD14
and CD83, and positive for CD45, CD80, CD1a, CD86, HLA-
DR, and CD11c. Full length human 1,4 N-acetylgalactosami-
nyltranserfase was cloned into a GFP expression vector and
sequenced. GD2 mRNA was transfected into immature DC at
day 5 of culture using Qiagen Transmessenger. Transfection
efﬁciency was determined by GFP ﬂuorescence at 48 hours
post-transfection via ﬂow cytometry. DC transfected with water
were used as a negative control. Cells were further matured with
tumor necrosis factor 
 (TNF 
) for an additional 24 hours
post-transfection. T cells were plated in 24 well plates and
co-cultured with autologous or allogeneic GD2 mRNA trans-
fected DC to prime the T cells. On day 8 of culture, the T cells
were restimulated, and T cell response against antigen loaded
DC, or water, was measured by the amount of IFN&gamm;
secreted using Elispot. The number of spots in each well were
counted and represent the amount of IFN&gamm; secreted by
Th1 cells. Of the GFP-positive transfected cells, 33% (range
31.4–35.0) expressed GD2 on the surface by ﬂow cytometry.
The amount and intensity of IFN secreted was signiﬁcantly
increased in mRNA transfected wells (mean of 31.13, range
3–60 spots) compared to water (mean of 16.38, range 3–36
spots). In addition the IFN secreted by individual T helper
cells was signiﬁcantly higher in the allogeneic transfected wells
(mean of 47.5, range 30–57 spots) versus the autolgous wells
(mean of 16.5, range 3–28 spots). These data demonstrate that
we are able to transfect DC with GD2 mRNA using a non-viral
method and elicit an allogeneic immune response in vitro.
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GRAFT-VERSUS-BRAIN TUMOR EFFECT IN A CHILD WITH ANAPLASTIC
ASTROCYTOMA AFTER CORD BLOOD TRANSPLANTATION FOR THERA-
PY-RELATED LEUKEMIA
Hudspeth, M.P.1, Cohen, K.1, Chen, A.R.1 1Sidney Kimmel Compre-
hensive Cancer Center at Johns Hopkins, Baltimore, MD.
The graft-versus-tumor effect has been described for several
solid tumors, but little is known regarding the susceptibility of
brain tumors to allogeneic immune responses. We report a case
of cord blood transplantation for therapy-related acute myelog-
enous leukemia in a 7-year old boy with active high-grade
astrocytoma lesions. This represents the ﬁrst reported case of a
pediatric patient undergoing transplantation for therapy-related
leukemia with a coexisting brain tumor. The patient received a
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